Strong scientific research force "blessing" Banlangen of Guangzhou Pharmaceutical Group insists on keeping integrity and innovation

On April 22, at the 2021 China Pharmaceutical Terminal Marketing Summit with the theme of "Directly hitting the C-end • Melting efficiency", Banlangen in the Baiyun Mountain and Huang exhibition area was watched by representatives from pharmacies all over the country. According to Baiyunshan and Huang, “consumers have a new understanding of Chinese medicine. From last year to the present, Baiyunshan Banlangen has been in short supply, and companies continue to work overtime to produce.”

At present, Baiyunshan Banlangen is accelerating the implementation of scientific research results. In October 2020, Baiyunshan and Huang signed a memorandum on the transformation of Baiyunshan Isatis root research results in Macau with the State Key Laboratory of Respiratory Diseases of Guangzhou Medical University and Macau University of Science and Technology. Guangzhou Pharmaceutical Group will also take the scientific research industrialization of Banlangen and compound Banlangen as the starting point, and continue to innovate through the layout of the entire industry chain to make Chinese medicine go global.

To

Baiyunshan and Huang lead the innovation trend of Chinese patent medicines such as Banlangen

Focusing on inheriting the essence, keeping integrity and innovation as the mainline, insisting on giving full play to the characteristic advantages and diversified value of traditional Chinese medicine, more and more mainstream pharmaceutical companies are exploring the inheritance and innovation of traditional Chinese medicine in the new era. 

Banlangen is a household name and has always been sought after by consumers. It is understood that Baiyun Mountain and Huang have endless innovations in this product. As early as 2007, Guangzhou Pharmaceutical Group initiated the Isatis mechanism research project. For more than ten years, it has cooperated with the Guangzhou Institute of Respiratory Health and the National Key Laboratory of Respiratory Diseases to integrate the mainland. And Hong Kong, Macao, and other superior scientific research institutions, to achieve coordinated research on major scientific research topics. In 2009, Baiyunshan Banlangen, as the first Chinese medicine funded by NIH in the United States, opened a precedent for Sino-Western cooperative research. After the Guangdong-Hong Kong-Macao Greater Bay Area became a national strategy, Guangzhou Pharmaceutical Group actively promoted the industrialization of Baiyunshan Banlangen scientific research results to settle in Macau. At the same time, Guangzhou Pharmaceutical Group continues to deepen its cooperation with the University of Macau and other universities in Macau, relying on the State Key Laboratory of the University of Macau-the State Key Laboratory of Quality Research of Traditional Chinese Medicine to jointly build the Macau Traditional Chinese Medicine R&D Center, develop the industry chain of authentic medicinal materials, and study classic names. square. 

"The origin of all product innovations comes from demand. The demand for Baiyunshan Banlangen in short supply is the objective demand of consumers for branded products. The recognition of Chinese medicine by different consumers around the world forces companies to pay more attention to product innovation. Baiyunshan and Huang based on market demand Continue to carry out secondary development, and propose refining ancient medicines and refining general medicines', using modern technology to make old medicines have better curative effects while paying attention to the development of new indications for Chinese patent medicines." According to the person in charge of Baiyun Mountain and Huang Chinese Medicine At present, the company is striving to be a pioneer in innovation with the help of the Guangdong-Hong Kong-Macao Greater Bay Area's policy support for Chinese medicine.

Baiyun Mountain and Huang help to build a new dual-cycle development pattern

At present, Baiyunshan Isatis root is moving from the basic research stage to the critical moment of industrial transformation and upgrading. Baiyunshan and Huang will continue to focus on quality improvement, process optimization, and evidence-based research to promote the industrialization of new Isatis root products in Macau and the Mainland. The bridgehead of the Macau International Headquarters of the Pharmaceutical Group uses the resources of the Portuguese language of Macau and the resources of the “Belt and Road” to bring Chinese medicine to the world.

Currently, Baiyunshan, and Huang's two leading products, compound Danshen tablets and Banlangen granules, account for more than 50% of the market share in similar markets. At the aforementioned summit, Baiyun Mountain and Huang and the common people's pharmacy held the launch ceremony of the compound Danshen tablet "Pan Xin Bao" caring heart and brain health and welfare action. Baiyunshan and Huang practiced the corporate philosophy of "Guangyao Baiyunshan·Love and Love", the world's first "Family Expired Drug Recycling Mechanism", setting the world's largest "Family Expired Drug Recycling Public Welfare Activity" Guinness World Record, benefiting 600 million people and recycling Over 1,800 tons of expired medicines. In addition, more than 10 GAP bases such as Banlangen in Fuyang, Anhui have not only solved the quality problems o7f medicinal materials but also provided poverty alleviation measures for farmers everywhere.